Investment Considerations Demonstrated prolonged life with 59% decreased risk of death in an integrated meta-analysis across the HEALEY ALS Platform Trial and RESCUE-ALS Trial with CNM-AU8 30 mg dose compared to PRO-ACT matched placebo over long-term follow-up (p=.004) 19.3 month survival difference for CNM-Au8 ALS treated participants versus placebo in RESCUE-ALS Trial Multiple near-term milestones, … Continue reading “Clene Inc. (NASDAQ: CLNN)”
Symbol | Release | Time |
---|---|---|
{{ release.qmtopics.qmsymbol[0].symbol }} | {{ release.headline }} | {{ release.datetime | amDateFormat:'hh:mm A'}} |
SeriousTraders is part of the IBN (InvestorBrandNetwork). Other brands within the investor brand network include: